Malifutai

Based on the analysis of data from non-clinical studies and completed clinical studies (MLFT-protocol-01), it is necessary to further explore the safe dosage range of BJY-801 for single administration in healthy Chinese adults and evaluate the safety and tolerability of a single intravenous infusion of BJY-801 in healthy humans, so as to provide a basis for formulating multiple tolerance and pharmacokinetic studies and dosing regimens for Phase II clinical trials.

To observe the safety and tolerability of a single infusion of molifopeptide for injection in healthy subjects, evaluate the safe dosage range of a single administration of molifopeptide for injection in healthy subjects and its pharmacokinetic characteristics in healthy Chinese subjects, and provide a basis for formulating multiple tolerance and pharmacokinetic studies and dosing regimens for Phase II clinical trials.